A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity

AIMS: Prasugrel is a novel thienopyridine P2Y(12) adenosine diphosphate (ADP) receptor antagonist that inhibits ADP-mediated platelet activation and aggregation. Accordingly, it may be useful in reducing platelet-related ischaemia in sickle cell disease (SCD). Exposure to prasugrel's active met...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jakubowski, Joseph A, Zhou, Chunmei, Small, David S, Winters, Kenneth J, Lachno, D Richard, Frelinger, Andrew L, Howard, Jo, Mant, Timothy G, Jurcevic, Stipo, Payne, Christopher D
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Science Inc 2013
Témata:
Clinical Trials
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3690102/
https://ncbi.nlm.nih.gov/pubmed/23171128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12042
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky